



*Erasmus School of Health Policy & Management
and Erasmus School of Economics declare that the*

Thesis of the Year Award 2026 Health Economics

was won by

Aida van Riel

'Cost-effectiveness of inavolisib in combination with palbociclib and fulvestrant versus palbociclib and fulvestrant alone for the first-line treatment of PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer in the Netherlands'

Rotterdam, October 1, 2026

*On behalf of Erasmus School of Health Policy & Management (ESHPM) and
Erasmus School of Economics (ESE)*

Programme director

Dr Vivian Reckers-Droog (ESHPM)